Limits...
Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium.

Wang B, Jiang W, Yan H, Zhang X, Yang L, Deng L, Singh GK, Pan J - Int J Nanomedicine (2011)

Bottom Line: The resulting nanoparticles (NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta potential >-10 mV, and encapsulation efficiency >50%.Specifically, the bioactivity of the insulin released from the NPs was maintained.Owing to encapsulation, both for hydrophobic and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA NPs in combination therapy.

View Article: PubMed Central - PubMed

Affiliation: Bioengineering College, Chongqing University, Chongqing, People's Republic of China.

ABSTRACT
This study concerns the encapsulation and controlled release of both hydrophobic and hydrophilic medications with one polymer, which are delivered together as a combined therapy to treat diseased tissue. To test our hypothesis that the novel PEG-graft-PLA (PEG, polyethylene glycol; PLA, polylactic acid) can deliver both the hydrophobic and hydrophilic medications on account of its amphiphility, charge, and graft structure, PEG-graft-PLA (molecular weight of PEG = 1900) with very low critical micelle concentration was synthesized. One hydrophilic (insulin) and one hydrophobic (naproxen) model medication were loaded in separately during its self-assembly in aqueous solution. The resulting nanoparticles (NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta potential >-10 mV, and encapsulation efficiency >50%. The NPs realized controlled release of insulin and naproxen for over 24 and 160 hours, respectively. Specifically, the bioactivity of the insulin released from the NPs was maintained. Owing to encapsulation, both for hydrophobic and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA NPs in combination therapy.

Show MeSH
CMC determination of PEG-graft-PLA. (A) Excitation spectra of pyrene from 321 to 340 nm as a function of PEG-graft-PLA concentration in water. (B) Intensity ratio (329/327) of pyrene versus logarithm concentration of PEG-graft-PLA. The CMC was determined by taking the midpoint in the plot of (B), which was 2.0 × 10−3 mg/mL.Abbreviations: CMC, critical micelle concentration; PEG, polyethylene glycol; PLA, polylactic acid.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3141871&req=5

f1-ijn-6-1443: CMC determination of PEG-graft-PLA. (A) Excitation spectra of pyrene from 321 to 340 nm as a function of PEG-graft-PLA concentration in water. (B) Intensity ratio (329/327) of pyrene versus logarithm concentration of PEG-graft-PLA. The CMC was determined by taking the midpoint in the plot of (B), which was 2.0 × 10−3 mg/mL.Abbreviations: CMC, critical micelle concentration; PEG, polyethylene glycol; PLA, polylactic acid.

Mentions: The CMC of PEG-graft-PLA in water was 2.0 × 10−3 mg/mL, as shown in Figures 1A and 1B, which was comparable to PEG-block-PLA16 and one order lower than Tween 80 (ie, 1.4 × 10−2 mg/mL), one of the most commonly used surfactants in particle preparation. The result showed its good surfactivity.


Novel PEG-graft-PLA nanoparticles with the potential for encapsulation and controlled release of hydrophobic and hydrophilic medications in aqueous medium.

Wang B, Jiang W, Yan H, Zhang X, Yang L, Deng L, Singh GK, Pan J - Int J Nanomedicine (2011)

CMC determination of PEG-graft-PLA. (A) Excitation spectra of pyrene from 321 to 340 nm as a function of PEG-graft-PLA concentration in water. (B) Intensity ratio (329/327) of pyrene versus logarithm concentration of PEG-graft-PLA. The CMC was determined by taking the midpoint in the plot of (B), which was 2.0 × 10−3 mg/mL.Abbreviations: CMC, critical micelle concentration; PEG, polyethylene glycol; PLA, polylactic acid.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3141871&req=5

f1-ijn-6-1443: CMC determination of PEG-graft-PLA. (A) Excitation spectra of pyrene from 321 to 340 nm as a function of PEG-graft-PLA concentration in water. (B) Intensity ratio (329/327) of pyrene versus logarithm concentration of PEG-graft-PLA. The CMC was determined by taking the midpoint in the plot of (B), which was 2.0 × 10−3 mg/mL.Abbreviations: CMC, critical micelle concentration; PEG, polyethylene glycol; PLA, polylactic acid.
Mentions: The CMC of PEG-graft-PLA in water was 2.0 × 10−3 mg/mL, as shown in Figures 1A and 1B, which was comparable to PEG-block-PLA16 and one order lower than Tween 80 (ie, 1.4 × 10−2 mg/mL), one of the most commonly used surfactants in particle preparation. The result showed its good surfactivity.

Bottom Line: The resulting nanoparticles (NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta potential >-10 mV, and encapsulation efficiency >50%.Specifically, the bioactivity of the insulin released from the NPs was maintained.Owing to encapsulation, both for hydrophobic and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA NPs in combination therapy.

View Article: PubMed Central - PubMed

Affiliation: Bioengineering College, Chongqing University, Chongqing, People's Republic of China.

ABSTRACT
This study concerns the encapsulation and controlled release of both hydrophobic and hydrophilic medications with one polymer, which are delivered together as a combined therapy to treat diseased tissue. To test our hypothesis that the novel PEG-graft-PLA (PEG, polyethylene glycol; PLA, polylactic acid) can deliver both the hydrophobic and hydrophilic medications on account of its amphiphility, charge, and graft structure, PEG-graft-PLA (molecular weight of PEG = 1900) with very low critical micelle concentration was synthesized. One hydrophilic (insulin) and one hydrophobic (naproxen) model medication were loaded in separately during its self-assembly in aqueous solution. The resulting nanoparticles (NPs) were narrowly distributed and spherical, with average particle size around 200 nm, zeta potential >-10 mV, and encapsulation efficiency >50%. The NPs realized controlled release of insulin and naproxen for over 24 and 160 hours, respectively. Specifically, the bioactivity of the insulin released from the NPs was maintained. Owing to encapsulation, both for hydrophobic and hydrophilic medicines, and NPs obtained with similar size and zeta potential, as well as maintenance of bioactivity of loaded protein, we expect the applications of PEG-graft-PLA NPs in combination therapy.

Show MeSH